Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Dec;6(6):708-712.
doi: 10.21037/tlcr.2017.09.08.

Blood-based biomarkers in lung cancer: prognosis and treatment decisions

Meng Xu-Welliver  1 , David P Carbone  2
Affiliations
Review

Blood-based biomarkers in lung cancer: prognosis and treatment decisions

Meng Xu-Welliver et al. Transl Lung Cancer Res. 2017 Dec.

Abstract

Despite recent advances, non-small cell lung cancer (NSCLC) remains a devastating disease with overall poor prognosis. Major contributing factors include obstacles to diagnosing the disease early in its course during the asymptomatic stage as well as diversity and complexity of its biology underlying tumorigenesis and tumor progression. Advances in molecularly targeted therapies which drives the development of personalized cancer care require precise and comprehensive understanding of tumor biology, not only at the time of diagnosis but also during treatment course and surveillance. As lung tumor tissue can be difficult to obtain without invasive and potentially risky procedures, it is difficult to monitor treatment response with serial tissue biopsies. Development of non-invasive but reliable blood based tumor markers has become an important research area. In this review, we focus on the following circulating biomarkers that have been identified in recent years: circulating tumor cells (CTCs); circulating cell-free nucleic acids, such as circulating tumor DNA (ctDNA) and microRNA (miR); and other biomarkers such as genomic and proteomic features. These biomarkers not only have prognostic values, but also can help guild treatment decisions by monitoring tumor burden, detecting minimal residual disease and/or recurrent disease, as well as monitoring evolution of genetic alterations throughout the treatment course.

Keywords: Circulating tumor DNA (ctDNA); circulating tumor cells (CTCs); liquid biopsy; microRNA (miR); prognostic biomarker.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Utility of circulating tumor markers in lung cancer.
See this image and copyright information in PMC

References

    1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70. 10.1016/S0092-8674(00)81683-9 - DOI - PubMed
    1. Nagrath S, Sequist LV, Maheswaran S, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007;450:1235-9. 10.1038/nature06385 - DOI - PMC - PubMed
    1. Hanssen A, Loges S, Pantel K, et al. Detection of circulating tumor cells in non-small cell lung cancer. Front Oncol 2015;5:207. 10.3389/fonc.2015.00207 - DOI - PMC - PubMed
    1. Xenidis N, Perraki M, Kafousi M, et al. Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. J Clin Oncol 2006;24:3756-62. 10.1200/JCO.2005.04.5948 - DOI - PubMed
    1. Cohen SJ, Punt CJ, Iannotti N, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:3213-21. 10.1200/JCO.2007.15.8923 - DOI - PubMed